Singapore Ministers and Business China Delegation Visit Lion TCR to Explore High-Quality Biotech Collaboration

Disclaimer: Due to limited proficiency, errors are inevitable, and some information may not be the most up-to-date. Comments pointing out any inaccuracies are welcome. This article is only an introduction to pharmaceuticals related to healthcare and is not a recommendation of treatment plans (if involved). This article does not constitute any investment advice.

(From left to right: Mr. He Zhixuan, President of Business China; Dr. Peng Xiaoming, CEO of Guangzhou Laien Biological Medicine Co., Ltd.; Dr. Koh Poh Koon, Senior Minister of State for Sustainability and the Environment & Manpower and Director of Business China; Mr. Tan See Leng, Minister of State for Trade and Industry & Culture, Community and Youth)

Dr. Xiaoming Peng, CEO of Guangzhou Laien Biological Medicine Co., Ltd., introduced to Minister Baokun Xu and Minister Shenghui Chen and their team the unique application and clinical progress of Laien Bio's use of mRNA technology combined with TCR-T cell therapy in solid tumors.

Guangzhou Laien Biological Medicine Co., Ltd. expands its focus to treating various tumors by upgrading its mRNA technology platform and AI-powered TCR target discovery platform. In addition to rapidly commercializing its first leading product for advanced liver cancer, Laien is also committed to the functional cure of chronic hepatitis B, as well as early- and mid-stage liver cancer and cancer prevention. The company is simultaneously developing cost-effective off-the-shelf products. Laien Biological focuses on delivering high-quality products and technological platforms, striving to be the best in its niche field. With a meticulous attitude and relentless efforts, it aims to become a global leader in the mRNA-encoded TCR-T cell therapy platform for treating multiple cancers.

Minister Xu Baokun expressed during the exchange: "We look forward to Chinese and Singaporean companies jointly promoting innovation and cooperation in the biotechnology field. On the road ahead, we hope that Guangzhou Laien Biological Medicine Co., Ltd. will continue to be driven by innovation, striving for breakthroughs in the biotechnology sector."

About Laien Bio

Lion TCR is a clinical-stage biotechnology company focused on TCR therapy. The company has pioneered the use of mRNA to encode TCRs, which has been applied in clinical trials for liver cancer treatment, demonstrating good safety and significant efficacy. Through an AI-powered TCR discovery platform, the company is expanding its range of targets and indications to provide innovative therapies for unresolved clinical issues. Additionally, the company has developed autologous cell therapy and established an off-the-shelf therapy product platform, including in vivo TCR-T therapy delivered via mRNA-LNP.

Source of the article:Laien Biological MedicineThing